Growth signalling, the axis that regulates it, and what happens when that regulation is bypassed.
The synergy between the two pathways is demonstrated in humans. The outcomes people buy it for are not — no trial has measured body composition or recovery from the combination.
One clears in half an hour and makes a pulse. The other binds albumin and holds a plateau for a week. And the version almost nobody uses is the only one with human trial data.
Same receptor, same pathway, same cascade as every other GHRH analogue. What differs is what was measured — and one storage property that a purity test cannot detect.
The original GHRH analogue, cleared by the FDA in 1997 and withdrawn for commercial reasons. Its short half-life is both its weakness and the reason it behaves naturally.
It raises growth hormone without the cortisol and prolactin that older compounds in its class produce. It also failed its only controlled clinical trial.
Two structural changes stop binding proteins capturing it, tripling potency and doubling half-life. The same edits remove the controls that existed for a reason.
